Schedule 13D ownership disclosure
Taysha Gene Therapies Inc
Security class unavailable · CUSIP: 877619106
Event date: 2022-10-21
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- Unavailable
- Percent of class
- 11.6000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-22-273891
- Form type
- SC 13D
- Filer
- Audentes Therapeutics, Inc.
- CIK
- CIK 1628738
- Filed
- Oct 31, 2022
- Reporting period
- Oct 21, 2022
- Description
- Schedule 13D beneficial ownership